Shuttle Pharmaceuticals ... (SHPH)
0.31
0.01 (4.52%)
At close: Apr 25, 2025, 3:58 PM
0.31
0.00%
After-hours: Apr 25, 2025, 07:46 PM EDT
Company Description
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy.
Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers.
The company was founded in 2012 and is based in Rockville, Maryland.
Shuttle Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Aug 31, 2022 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Dr. Anatoly Dritschilo M.D. |
Contact Details
Address: One Research Court Rockville, Maryland United States | |
| Website | https://www.shuttlepharma.com |
Stock Details
| Ticker Symbol | SHPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001757499 |
| CUSIP Number | 825693203 |
| ISIN Number | US8256932034 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christopher Robert Cooper BBA, M.B.A., MBA | Interim Co-Chief Executive Officer |
| Dr. Anatoly Dritschilo M.D. | Co-Founder, Co-Chief Executive Officer, Chief Scientific Officer & Chairman of the Board |
| Peter Dale Dritschilo M.B.A., M.D. | President & Chief Operating Officer |
| Timothy J. Lorber CPA | Chief Financial Officer |
| Dr. Milton Brown CSC, M.D., Ph.D. | Co-Founder |
| Dr. Mira Jung Ph.D. | Co-Founder & Chief Scientific Officer for Biology |
| Dr. Tyvin A. Rich M.D. | Chief Clinical Officer & Chief Medical Officer |
| Michael P. Vander Hoek | Vice President for Operations and Regulatory |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2025 | PRER14A | Filing |
| Apr 21, 2025 | 8-K | Current Report |
| Apr 21, 2025 | DEFR14A | Filing |
| Apr 10, 2025 | PRER14A | Filing |
| Apr 10, 2025 | 8-K | Current Report |
| Apr 04, 2025 | 8-K | Current Report |
| Apr 02, 2025 | 3 | Filing |
| Mar 31, 2025 | ARS | Filing |
| Mar 31, 2025 | DEF 14A | Filing |
| Mar 31, 2025 | 8-K | Current Report |